Is Nemus Bioscience price going to go crazy in April?

In defiance of relatively conflicting forward-looking signals, Nemus Bioscience reported solid returns over the last few months and may actually be approaching a breakup point. We found twenty-nine available fundamentals for Nemus Bioscience which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Nemus Bioscience fundamentals including its Cash and Equivalents as well as the relationship between Earnings Per Share and Working Capital . As Nemus Bioscience is a penny stock we also strongly advise to check its Price to Book numbers. Use Nemus Bioscience to enhance returns of your portfolios. The stock experiences very speculative upward sentiment. The trend is possibly hyped up. Check odds of Nemus Bioscience to be traded at $0.5525 in 30 days.
Published over a year ago
View all stories for Emerald Bioscience | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Rifka Kats

This firm currently holds zero balance in liabilities. The company has Current Ratio of 0.1 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due. Nemus Bioscience dividends can provide a clue to current valuation of the stock. The firm is not expected to issue dividends this year as it trying to preserve or re-invest any of the funds available for distribution to stakeholders.

How important is Emerald Bioscience's Liquidity

Emerald Bioscience financial leverage refers to using borrowed capital as a funding source to finance Emerald Bioscience ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Emerald Bioscience financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Emerald Bioscience's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Emerald Bioscience's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Emerald Bioscience's total debt and its cash.

Detailed Outlook On Emerald Bioscience

Nemus Bioscience has beta of -0.04. As returns on market increase, returns on owning Nemus Bioscience are expected to decrease at a much smaller rate. During bear market, Nemus Bioscience is likely to outperform the market. The latest price spikes of Nemus Bioscience may encourage investors to take a closer look at the firm as it closed today at a share price of 0.4 on 33120.000 in trading volume. The company executives were quite successful positioning the firm components to exploit market volatility in April 2019. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 7.2624. The very high volatility is mostly attributed to the latest market swings and not very good earning reports from some ot the Nemus Bioscience partners. Nemus Bioscience preserves 96.96% of probability of bankruptcy. Nemus Bioscience is selling at 0.442. That is 5.74 percent increase. Day high is 0.46. Nemus Bioscience Cash and Equivalents is increasing over the last 5 years. Further, Nemus Bioscience Free Cash Flow is relatively stable at the moment.
To conclude, our research shows that Nemus Bioscience is abnormally risky with very high odds of financial turmoil in the next two years. Our prevailing buy vs hold vs sell advice on the enterprise is Strong Sell.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Emerald Bioscience. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com